Crossmark

Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen

Crossref DOI link: https://doi.org/10.1245/s10434-026-19100-7

Published Online: 2026-02-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cuillerier, Natasha J. Stonebanks

Almarzooqi, Hamda

Villareal-Corpuz, Victor

Sabboobeh, Sarah

Prakash, Ipshita

Basik, Mark

Boileau, Jean Francois

Martel, Karyne

Meterissian, Sarkis

Pollak, Michael

Wong, Stephanie M.
License Information

Text and Data Mining valid from 2026-02-07

Version of Record valid from 2026-02-07
More Information

Article History

Received: 31 October 2025

Accepted: 6 January 2026

First Online: 7 February 2026

Disclosure

: Stephanie Wong reports honoraria from AstraZeneca, Novartis, Pfizer, and Merck, outside of the submitted work.

Document is current

Any future updates will be listed below